Evidence map›Paper›PMID 24832167›Full record

ArticleChest2014

Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis.

Jade Jaffar, Sofia Unger, Tamera J Corte, Michael Keller, Paul J Wolters, Luca Richeldi, Stefania Cerri, Cecilia M Prêle, Philip M Hansbro, William Scott Argraves and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Chest, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2020
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Defining the versican interactome in lung health and disease.American journal of physiology. Cell physiology · 2022
    Review
  11. Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues.Matrix biology : journal of the International Society for Matrix Biology · 2022
    Review
  12. Article
  13. Review
  14. Extracellular matrix-derived peptides in tissue remodeling and fibrosis.Matrix biology : journal of the International Society for Matrix Biology · 2020
    Review
  15. Article
  16. Article
  17. Review
  18. Matrix biomechanics and dynamics in pulmonary fibrosis.Matrix biology : journal of the International Society for Matrix Biology · 2018
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jade JaffarThe Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia; Discipline of Pharmacology, The University of Sydney, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, and Royal Prince Alfred Hospital (Sydney Local Health District), Sydney, NSW, Australia. Electronic address: jade.jaffar@sydney.edu.au.
Sofia UngerThe Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia.
Tamera J CorteSydney Medical School, The University of Sydney, and Royal Prince Alfred Hospital (Sydney Local Health District), Sydney, NSW, Australia.
Michael KellerSydney Medical School, The University of Sydney, and Royal Prince Alfred Hospital (Sydney Local Health District), Sydney, NSW, Australia.
Paul J WoltersCardiovascular Research Institute, University of California San Francisco, San Francisco, CA.
Luca RicheldiDepartment of Respiratory Diseases, University Hospital of Modena, University of Modena and Reggio Emilia, Modena, Italy; Department of Interstitial Lung Disease, University of Southampton, Southampton, England.
Stefania CerriDepartment of Respiratory Diseases, University Hospital of Modena, University of Modena and Reggio Emilia, Modena, Italy.
Cecilia M PrêleLung Institute of Western Australia, Centre for Asthma Allergy and Respiratory Research, The University of Western Australia, Perth, WA, Australia; Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology, The University of Western Australia and Western Australian Institute for Medical Research, Perth, WA, Australia.
Philip M HansbroPriority Research Centre for Asthma and Respiratory Disease, The University of Newcastle and Hunter Medical Research Institute (HMRI), New Lambton Heights, NSW, Australia.
William Scott ArgravesDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC.
Rema A OliverSurgical and Orthopaedic Research Laboratories, Prince of Wales Clinical School, University of New South Wales, Randwick, NSW, Australia.
Brian G OliverThe Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia; School of Medical and Molecular Biosciences, The University of Technology Sydney, Sydney, NSW, Australia.
Judith L BlackThe Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia; Discipline of Pharmacology, The University of Sydney, Sydney, NSW, Australia.
Janette K BurgessThe Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia; Discipline of Pharmacology, The University of Sydney, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, and Royal Prince Alfred Hospital (Sydney Local Health District), Sydney, NSW, Australia.

Funding

Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis PathwayR01HL095067 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ARGRAVES, WILLIAM SCOTT · 2009 to 2012
$1.5M
NHLBI NIH HHS R01 HL095067
6 · The paper itself

Abstract

backgroundThe underlying mechanisms of idiopathic pulmonary fibrosis (IPF) are unknown. This progressive disease has high mortality rates, and current models for prediction of mortality have limited value in identifying which patients will progress. We previously showed that the glycoprotein fibulin-1 is involved in enhanced proliferation and wound repair by mesenchymal cells and, thus, may contribute to lung fibrosis in IPF.

methodsSerum, lung tissue, and lung function values were obtained from four independent locations (Sydney, NSW, and Perth, WA, Australia; San Francisco, CA; and Modena, Italy). Patients with IPF were followed for a minimum of 1 year and progression was defined as a significant decline in lung function or death. Primary parenchymal lung fibroblasts of 15 patients with and without IPF were cultured under nonstimulatory conditions. Fibulin-1 levels in serum, and secreted or deposited by fibroblasts, were measured by western blot and in lung tissue by immunohistochemistry.

resultsSerum fibulin-1 levels were increased in patients with IPF compared with subjects without lung disease (P = .006). Furthermore, tissue fibulin-1 levels were increased in patients with IPF (P = .02) and correlated negatively with lung function (r = -0.9, P < .05). Primary parenchymal fibroblasts from patients with IPF produced more fibulin-1 than those from subjects without IPF (P < .05). Finally, serum fibulin-1 levels at first blood draw predicted disease progression in IPF within 1 year (area under the curve , 0.71; 95% CI, 0.57-0.86; P = .012).

conclusionsFibulin-1 is a novel potential biomarker for disease progression in IPF and raises the possibility that it could be used as a target for the development of new treatments.

Indexed as

AgedAged, 80 and overAustraliaBiomarkersBlotting, WesternCalcium-Binding ProteinsCell Culture TechniquesDisease ProgressionFemaleFibroblastsFollow-Up StudiesHumansIdiopathic Pulmonary FibrosisImmunohistochemistryItalyMaleBiomarkersCalcium-Binding Proteinsfibulin

Identifiers

PMID24832167
PMCPMC4188142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.